Edit the message. Rewrite the future.
Editing a single letter on RNA to modulate a biological pathway. Our mission is to deliver the promise of genetic medicines to complex prevalent diseases.
Supporting patients with alpha-1
People with AATD have clinical manifestations within the liver and lung organs. AATD is an inherited genetic disorder caused by a single letter change in a gene called SERPINA1. Our approach holds the potential of providing clinical benefits implicated in this disease.
Our science
Our approach to edit RNA involves redirecting a naturally occurring editing process that’s inside every cell in the human body. This is accomplished by delivering a chemically modified RNA that helps to target precisely the change we want to make. Our proprietary platform called Oligonucleotide Promoted Editing of RNA (OPERA®) enables us to discover and develop these drug candidates.
Our pipeline
Our pipeline programs demonstrate the versatility of our approach in bringing precision and tunability to genetic medicines to address a broad range of rare and highly prevalent diseases. We can repair proteins caused by genetic mutations or alter proteins to activate a biological pathway.
View our pipelineNews and media
Career opportunities
Write the next chapter of your career with Korro, where we are developing a novel class of medicines.
See our opportunities